Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Valentine

Showing results (81-90 of 97) with videos related to

Pageof 10
Sort By:
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 18, 2024
A Randomized Phase II Study of Efmarodocokin Alfa, an interleukin-22 Agonist, Versus Vedolizumab in Patients With Ulcerative ColitisSilvio Danese, Michael E Rothenberg, Jeremy J Lim, et al.
Oncotarget|October 13, 2015
MicroRNA-146a constrains multiple parameters of intestinal immunity and increases susceptibility to DSS colitisMarah C Runtsch, Ruozhen Hu, Margaret Alexander, et al.
Alimentary Pharmacology & Therapeutics|June 6, 2003
Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trialW J Sandborn, B E Sands, D C Wolf, et al.
The American Journal of Gastroenterology|October 15, 2009
NOD2 mutations and anti-Saccharomyces cerevisiae antibodies are risk factors for Crohn's disease in African AmericansThemistocles Dassopoulos, Geoffrey C Nguyen, Monica Vladut Talor, et al.
The American Journal of Gastroenterology|October 16, 2013
EMerging BiomARKers in Inflammatory Bowel Disease (EMBARK) study identifies fecal calprotectin, serum MMP9, and serum IL-22 as a novel combination of biomarkers for Crohn's disease activity: role of cross-sectional imagingWilliam A Faubion, Joel G Fletcher, Sharon O'Byrne, et al.
Gut|April 11, 2006
Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trialG Van Assche, W J Sandborn, B G Feagan, et al.
The Journal of Infectious Diseases|April 11, 2001
Residual human immunodeficiency virus (HIV) Type 1 RNA and DNA in lymph nodes and HIV RNA in genital secretions and in cerebrospinal fluid after suppression of viremia for 2 yearsH F Günthard, D V Havlir, S Fiscus, et al.
Cell Host & Microbe|February 15, 2019
Expansion of Bacteriophages Is Linked to Aggravated Intestinal Inflammation and ColitisLasha Gogokhia, Kate Buhrke, Rickesha Bell, et al.
Medrxiv : the Preprint Server for Health Sciences|February 19, 2024
<i>TNF</i> promoter hypomethylation is associated with mucosal inflammation in IBD and anti-TNF responseDaniel S Levic, Donna Niedzwiecki, Apoorva Kandakatla, et al.
Gastro Hep Advances|September 17, 2024
<i>TNF</i> Promoter Hypomethylation Is Associated With Mucosal Inflammation in IBD and Anti-TNF ResponseDaniel S Levic, Donna Niedzwiecki, Apoorva Kandakatla, et al.
Pageof 10

Showing results (81-90 of 97) with videos related to

Sort By:
Pageof 10
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 18, 2024
A Randomized Phase II Study of Efmarodocokin Alfa, an interleukin-22 Agonist, Versus Vedolizumab in Patients With Ulcerative ColitisSilvio Danese, Michael E Rothenberg, Jeremy J Lim, et al.
Oncotarget|October 13, 2015
MicroRNA-146a constrains multiple parameters of intestinal immunity and increases susceptibility to DSS colitisMarah C Runtsch, Ruozhen Hu, Margaret Alexander, et al.
Alimentary Pharmacology & Therapeutics|June 6, 2003
Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trialW J Sandborn, B E Sands, D C Wolf, et al.
The American Journal of Gastroenterology|October 15, 2009
NOD2 mutations and anti-Saccharomyces cerevisiae antibodies are risk factors for Crohn's disease in African AmericansThemistocles Dassopoulos, Geoffrey C Nguyen, Monica Vladut Talor, et al.
The American Journal of Gastroenterology|October 16, 2013
EMerging BiomARKers in Inflammatory Bowel Disease (EMBARK) study identifies fecal calprotectin, serum MMP9, and serum IL-22 as a novel combination of biomarkers for Crohn's disease activity: role of cross-sectional imagingWilliam A Faubion, Joel G Fletcher, Sharon O'Byrne, et al.
Gut|April 11, 2006
Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trialG Van Assche, W J Sandborn, B G Feagan, et al.
The Journal of Infectious Diseases|April 11, 2001
Residual human immunodeficiency virus (HIV) Type 1 RNA and DNA in lymph nodes and HIV RNA in genital secretions and in cerebrospinal fluid after suppression of viremia for 2 yearsH F Günthard, D V Havlir, S Fiscus, et al.
Cell Host & Microbe|February 15, 2019
Expansion of Bacteriophages Is Linked to Aggravated Intestinal Inflammation and ColitisLasha Gogokhia, Kate Buhrke, Rickesha Bell, et al.
Medrxiv : the Preprint Server for Health Sciences|February 19, 2024
<i>TNF</i> promoter hypomethylation is associated with mucosal inflammation in IBD and anti-TNF responseDaniel S Levic, Donna Niedzwiecki, Apoorva Kandakatla, et al.
Gastro Hep Advances|September 17, 2024
<i>TNF</i> Promoter Hypomethylation Is Associated With Mucosal Inflammation in IBD and Anti-TNF ResponseDaniel S Levic, Donna Niedzwiecki, Apoorva Kandakatla, et al.
Pageof 10